Drug · DIN 00297763
BICNU
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 19, 2017; first marketed December 31, 1975.
- Drug Identification Number (DIN)
- 00297763
- Company (DIN owner)
- Marcan Pharmaceuticals Inc.Ottawa, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Carmustine L01AD01
- Class
- Human
- Record last updated
- June 27, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| CARMUSTINE | 100 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- September 19, 2017: NOC 19829New Drug Submission (NDS) · Transfer of drug identification number
- February 7, 2014: NOC 15217New Drug Submission (NDS) · Transfer of drug idnetification numbers
- September 2, 2005: NOC 7350New Drug Submission (NDS) · Manufacturer name change
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “bicnu”. A notice may cover another product or only some lots: read it to see what it covers.
- BiCNU (carmustine for injection U.S.P.) Lyophilized Powder - Shortage of Canadian labelled BiCNU and replacement with U.S. labelled stock - Notice to HospitalsSeptember 3, 2013 · Drugs · Product safety - Supply
- BiCNU (carmustine for injection, USP) 100 mg/vial - Risk of Myelosuppression, Pulmonary Toxicity, Renal and Hepatic Toxicity as a Result of Overfilled Vials - Notice to HospitalsSeptember 6, 2012 · Drugs
- BiCNU (carmustine for injection) - Type I Recall due to Risk of Infection - Notice to HospitalsJanuary 5, 2010 · Drugs
Other DINs named BICNU
- DIN 02555093 · Cancelled Post Market